UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 192

Sortiert nach

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

The New England journal of medicine, 2023-08, Vol.389 (6), p.491-503

2023

Link zum Volltext

Verfügbarkeit prüfen

Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer

Nature reviews. Clinical oncology, 2021-09, Vol.18 (9), p.547-557

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

The lancet oncology, 2016-03, Vol.17 (3), p.299-308

2016

Link zum Volltext

Verfügbarkeit prüfen

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

The lancet oncology, 2014, Vol.15 (1), p.e42-e50

2014

Link zum Volltext

Verfügbarkeit prüfen

Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis

Cell, 2014-02, Vol.156 (5), p.1002-1016

2014

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

Journal of clinical oncology, 2017-09, Vol.35 (25), p.2960-2974

2017

Link zum Volltext

Verfügbarkeit prüfen

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

Clinical cancer research, 2012-09, Vol.18 (18), p.4910-4918

2012

Link zum Volltext

Verfügbarkeit prüfen

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics

Molecular cancer therapeutics, 2013-02, Vol.12 (2), p.220-229

2013

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in surgically resectable non-small cell lung cancer

Journal of thoracic disease, 2018-02, Vol.10 (Suppl 3), p.S404-S411

2018

Link zum Volltext

Verfügbarkeit prüfen

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers

Journal of thoracic oncology, 2016-03, Vol.11 (3), p.414-419

2016

Link zum Volltext

Verfügbarkeit prüfen

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival

Journal of clinical oncology, 2015-09, Vol.33 (26), p.2877-2884

2015

Link zum Volltext

Verfügbarkeit prüfen

Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma

Journal of thoracic oncology, 2019-03, Vol.14 (3), p.482-493

2019

Link zum Volltext

Verfügbarkeit prüfen

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

Science translational medicine, 2013-12, Vol.5 (216), p.216ra177

2013

Link zum Volltext

Verfügbarkeit prüfen

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade

Journal of clinical oncology, 2019-12, Vol.37 (36), p.3546-3555

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Nature communications, 2023-07, Vol.14 (1), p.4238-4238, Article 4238

2023

Link zum Volltext

Verfügbarkeit prüfen

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers

JNCI : Journal of the National Cancer Institute, 2019-06, Vol.111 (6), p.575-583

2019

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

Journal for immunotherapy of cancer, 2020-09, Vol.8 (2), p.e001282

2020

Link zum Volltext

Verfügbarkeit prüfen

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling

Molecular cancer therapeutics, 2012-02, Vol.11 (2), p.485-491

2012

Link zum Volltext

Verfügbarkeit prüfen

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Journal of thoracic oncology, 2012-12, Vol.7 (12), p.1815-1822

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas

Nature communications, 2022-10, Vol.13 (1), p.6095-8, Article 6095

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2 -mutant lung cancers

Lung cancer (Amsterdam, Netherlands), 2016-09, Vol.99, p.53-56

2016

Link zum Volltext

Verfügbarkeit prüfen

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

Journal for immunotherapy of cancer, 2022-06, Vol.10 (6), p.e004688

2022

Link zum Volltext

Verfügbarkeit prüfen

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma

Modern pathology, 2013-04, Vol.26 (4), p.511-522

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 192

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(183)
Mit Volltextzugriff
(169)

Publikationsform

Artikel
(191)
Texte
(1)

Sprache

Englisch
(192)
Japanisch
(28)

Erscheinungsjahr

n.n

Thema

Science & Technology
(112)
Life Sciences & Biomedicine
(108)
Humans
(96)
Oncology
(90)
Lung Neoplasms - Drug Therapy
(53)
Aged
(49)
Male
(49)
Female
(48)
Middle Aged
(48)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(41)
Lung Neoplasms - Pathology
(40)
Lung Neoplasms - Genetics
(39)
Aged, 80 And Over
(33)
Lung Cancer
(33)
Adult
(31)
Mutation
(31)
Respiratory System
(31)
Carcinoma, Non-Small-Cell Lung - Pathology
(27)
Neoplasm Staging
(26)
Carcinoma, Non-Small-Cell Lung - Genetics
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics

Immunotherapy in surgically resectable non-small cell lung cancer

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival

Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2 -mutant lung cancers

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma

Suchergebnisse filtern